Floatz logo

Ritlecitinib

Mycosis Fungoides

Icahn School of Medicine at Mount SinaiSmall moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
81/ 100

Competitive context

50 Active assets in the Mycosis Fungoides cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
(+)-VINCRISTINE
Virogen Biotechnology Inc.
Phase 4BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
Mayo Clinic
Phase 4BBB
METHOTREXATE
Polish Lymphoma Research Group
Phase 4BBB

View all 50 →

Same molecule, other indications

Ritlecitinib is also rated in:

Alopecia AreataDormant
CCC
Indicative ·
52 / 100
View asset →
celiac diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →